Passenger leukocyte

Passenger Leukocyte is a term used in the field of transplantation immunology to describe leukocytes (white blood cells) that are transferred along with a transplanted organ or tissue from the donor to the recipient. These cells play a significant role in the immune response associated with transplantation, including the potential induction of graft-versus-host disease (GVHD) in certain types of transplants, as well as contributing to the graft's acceptance or rejection.

Overview

When an organ or tissue is transplanted from a donor to a recipient, it is not just the organ cells that are transferred. The graft includes a variety of cells, among which are the donor's leukocytes, referred to as passenger leukocytes. These cells can be of various types, including lymphocytes (T cells and B cells), monocytes, and dendritic cells, each playing a distinct role in the immune response following transplantation.

Role in Transplantation

The presence of passenger leukocytes in a graft can have both beneficial and detrimental effects on the outcome of the transplantation. On one hand, these cells can contribute to the immunological tolerance of the graft by the recipient's immune system, a process known as microchimerism. On the other hand, they can also initiate an immune response against the recipient's tissues, leading to complications such as GVHD, particularly in bone marrow and stem cell transplants.

Graft-versus-Host Disease (GVHD)

GVHD is a condition where the donor's immune cells attack the recipient's body. Passenger leukocytes are implicated in the initiation and propagation of this disease, especially the donor T cells. GVHD can manifest in various degrees of severity and can affect multiple organs, including the skin, liver, and gastrointestinal tract.

Transplant Rejection

Conversely, the recipient's immune system may recognize the passenger leukocytes as foreign and mount an immune response against the graft, leading to transplant rejection. This is a major challenge in transplantation, requiring the recipient to be on immunosuppressive drugs to prevent rejection.

Immunosuppression

To mitigate the risks associated with passenger leukocytes, recipients of transplants are often placed on immunosuppressive therapy. These drugs help suppress the immune response against the transplanted organ or tissue, reducing the risk of both GVHD and transplant rejection.

Research and Advances

Research in the field of transplantation immunology is ongoing, with studies focusing on understanding the precise role of passenger leukocytes in graft acceptance and rejection. Advances in this area could lead to improved strategies for managing transplant patients, potentially reducing the need for long-term immunosuppression and increasing the success rate of transplants.

Conclusion

Passenger leukocytes play a critical role in the outcome of organ and tissue transplants. Their dual ability to induce tolerance or trigger an immune response highlights the complexity of the immune system in the context of transplantation. Ongoing research and advances in immunosuppressive therapies continue to improve the prospects for transplant recipients.

‎ ‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian